Ben Sasse, the former Republican U.S. senator from Nebraska, has surpassed initial medical expectations after being diagnosed with stage 4 metastatic pancreatic cancer in December 2025. Initially given three to four months to live, Sasse credits “providence, prayer and a miracle drug” for his extended survival.
The “miracle drug” is a clinical trial medication called daraxonrasib, developed by Revolution Medicines, which has caused a 76% reduction in his tumors. Clinical data indicates that patients treated with daraxonrasib typically see their survival extended from around six months to approximately 13 months.
Sasse discussed his diagnosis, treatment, and personal reflections in an interview with Scott Pelley, which aired Sunday on “60 Minutes.” Additional segments of the interview are available in a special edition of “Things That Matter” on Paramount+, CBSNews.com, and YouTube.
In the interview, Sasse also touched on his views regarding the current state of American politics, expressing skepticism about the major political parties’ long-term vision. He stated, “Neither of these parties really have very big or good ideas about 2030 or 2050,” and criticized Congress for not addressing significant future challenges.
Why it matters
Pancreatic cancer remains one of the most lethal cancers, with limited treatment options and a low survival rate. Advances like daraxonrasib in clinical trials offer hope for extending patient lives even in advanced stages. Sasse’s public discussion also brings awareness to the impact of experimental therapies and the role of faith and personal determination in managing terminal illness.
Background
Stage 4 pancreatic cancer is characterized by metastatic spread, typically resulting in a poor prognosis with median survival often measured in months. New targeted therapies and clinical trials are a vital part of ongoing efforts to improve outcomes for patients with this aggressive cancer type. Sasse’s case illustrates both the potential and challenges of accessing innovative treatments.
Read more Politics stories on Goka World News.
Sources
This article is based on reporting and publicly available information from the following source: